PB1823: THE BONE MARROW MICROENVIRONMENT IN ACUTE MYELOID LEUKEMIA: THE ROLE OF MESENCHYMAL STEM CELLS AND THEIR IMPACT ON THE CLINICAL OUTCOME

類似資料

• Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
  著者:: Simona De Gregori, 等
  出版事項: (2023-06-01)
• PB1823: THE BONE MARROW MICROENVIRONMENT IN ACUTE MYELOID LEUKEMIA: THE ROLE OF MESENCHYMAL STEM CELLS AND THEIR IMPACT ON THE CLINICAL OUTCOME
  著者:: Ludovica Calabretta, 等
  出版事項: (2023-08-01)
• Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
  著者:: Nickolas Steinauer, 等
  出版事項: (2024-03-01)
• PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
  著者:: Minerva Montalvo Saavedra, 等
  出版事項: (2023-08-01)
• Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
  著者:: Naseema Gangat, 等
  出版事項: (2022-06-01)